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Use of a multiplex real-time PCR to study the incidence of human
metapneumovirus and human respiratory syncytial virus infections during
two winter seasons in a Belgian paediatric hospital
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ABSTRACT
Viruses are an important cause of acute respiratory tract infection (ARTI) in children. This study aimed
to develop and evaluate a rapid molecular diagnostic test (duplex real-time PCR) for human respiratory
syncytial virus (hRSV) and human metapneumovirus (hMPV), and to determine the frequency of these
two viruses as causative agents of ARTI in Belgium. Nasopharyngeal aspirates were collected over two
winter and spring seasons (November 2003 to May 2004 and November 2004 to May 2005) from children
aged <5 years with ARTI (n = 778). The duplex real-time PCR showed a linear range of 104)1010 cop-
ies ⁄mL for both hMPV and hRSV. Analysis of the stability of the hRSV and hMPV genomes revealed
that nasopharyngeal aspirates could be stored at room temperature for up to 1 month without
significant loss of detection. hRSV was detected by antigen testing and by real-time PCR; hMPV was
detected by real-time PCR only. The hRSV antigen test was less sensitive than PCR, and failed to detect
one-third of the hRSV infections. Overall, 54 (6.9%) and 306 (39.3%) of the 778 samples were positive for
hMPV and hRSV, respectively. Both viruses infected young infants, but the mean age of infants infected
by hRSV was lower than that of infants infected by hMPV (12 months vs. 17 months, respectively).
Keywords Acute respiratory tract infection, antigen testing, children, human metapneumovirus, human respir-
atory syncytial virus, real-time PCR
Original Submission: 11 June 2006; Revised Submission: 5 October 2006; Accepted: 24 November 2006
Clin Microbiol Infect 2007; 13: 504–509
INTRODUCTION
Acute viral respiratory tract infections (ARTIs) are
a leading cause of illness in both children and
adults. Most such infections are mild and self-
limiting, and are confined to the upper respirat-
ory tract. However, in infants and children, upper
respiratory tract infections may spread to the
lower respiratory tract, where they can cause
more severe infections and even death. The
causative agents are a variety of genetically
diverse viruses, including the influenza viruses,
human respiratory syncytial virus (hRSV), adeno-
viruses, rhinoviruses and coronaviruses. It is
accepted that hRSV is the most common cause
of lower respiratory tract infections among chil-
dren aged £3 years. Nevertheless, 15–35% of
cases of bronchiolitis and pneumonia in paediat-
ric patients are of unknown aetiology [1–4],
suggesting that other infectious agents may exist
in the respiratory tract and remain to be identi-
fied.
In 2001, van den Hoogen et al. [5] reported the
isolation of a new respiratory virus, human
metapneumovirus (hMPV), from nasopharyngeal
aspirates (NPAs) obtained from children. Since its
discovery, hMPV infection has been reported
worldwide, accounting for c. 7–10% of ARTI in
children [6–16]. The clinical symptoms observed
most frequently in hMPV-positive children are
cough, wheezing and dyspnoea [17]. Thus, based
on the clinical picture of ARTI in paediatric
populations, it is currently impossible to distin-
guish between hRSV and hMPV infection [11].
In previous years, using hRSV and influenza
antigen testing only, a pathogen was identified in
OLV Hospital, Aalst, Belgium for <30% of cases
of ARTI in children. The high incidence of hRSV
infections, the relatively high incidence of hMPV
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infections described in the literature, and the
possibly severe illness associated with both
viruses, emphasised the need for a reliable,
sensitive and user-friendly diagnostic test for the
detection of both these viruses in NPAs. Testing
for the presence of both pathogens would also
enable co-infections to be documented [18].
Accordingly, the present study describes the
development of a real-time PCR for screening
NPAs for both hRSV and hMPV. Using this assay,
NPAs from paediatric patients with symptoms of
ARTI were analysed in retrospective (2003–2004)
and prospective (2004–2005) studies, and the
effectiveness of antigen testing and the multiplex
real-time PCR were compared for the detection of
hRSV.
MATERIALS AND METHODS
Specimen collection and non-molecular detection assays
Between 1 November 2003 and 31 May 2004, and between 1
November 2004 and 31 May 2005, NPAs were collected from
all infants (aged £5 years) who presented with symptoms of
ARTI at the OLV Hospital (54 paediatric beds). All infants
included in the study suffered from a respiratory infection and
had respiratory distress. Each infant was examined by a
paediatrician, and an NPA was obtained from each infant with
dyspnoea and ⁄ or wheezing whose respiratory condition was
sufficiently poor to require evaluation of the degree of
hypoxaemia by pulse oxymetry. A decision with respect to
hospitalisation or ambulatory treatment was then made on the
basis of the degree of hypoxaemia and the clinical and
respiratory status of each child.
All NPAs were tested for hRSV using the hRSV Respistrip
(Coris Bioconcept, Gembloux, Belgium). In addition, at the
request of the clinician and in line with the national
surveillance data, the presence of influenza A virus antigen
was investigated for a small proportion of the samples
(Virion; Serion Immundiagnostica, Wu¨rzburg, Germany). The
samples collected between 1 November 2003 and 31 May
2004 were stored at )70C until batch testing. The samples
collected between 1 November 2004 and 31 May 2005 were
analysed on a daily basis for the presence of hRSV and hMPV
RNA by the real-time PCR described in this study (see
below).
RNA extraction, reverse transcription, real-time PCR and
sequencing
Virus RNA was extracted from 140 lL of NPA with a QIAamp
Viral RNA Mini Kit (Qiagen, Venlo, The Netherlands), used
according to the manufacturer’s protocol. The resulting RNA
(10 lL) was then reverse-transcribed with random hexamer
primers in 20-lL volumes using the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA).
hRSV and hMPV cDNA sequences were amplified and
detected in a multiplex real-time PCR on the ABI Prism 7000
sequence detection system (Applied Biosystems). The hMPV
primers and probe (Table 1) were designed to cover most of
the known genetic variants (based on Maertzdorf et al. [19],
adapted according to recent sequence information available in
GenBank). Primers and probe targeted a part of the hMPV
nucleoprotein (N) gene (163 bp). The hRSV primers and probe
were designed using Primer Express software (Applied Bio-
systems) as part of the present study, and target the nucleo-
protein (N) genes of both hRSV-A and hRSV-B (163 bp). Each
25-lL reaction contained 12.5 lL Universal Mastermix (Ap-
plied Biosystems), 5 lL cDNA, 300 nM each hRSV primer and
200 nM hRSV probe (VIC-TAMRA-labelled), and 600 nM each
hMPV primer and 200 nM hMPV probe (FAM-TAMRA-
labelled). PCR amplification conditions comprised 10 min at
95C, followed by 45 cycles of 15 s at 95C and 1 min at 60C.
Amplicon sequencing for confirmation of identity was
performed on a random selection of positive samples (n = 5)
with a CEQ Dye Terminator Cycle Sequencing (DTCS) Quick
Start Kit (Analis, Suarle´e, Belgium). Sequencing reactions were
analysed on a CEQ 8000 Capillary Sequencer (Beckman
Coulter, Fullerton, CA, USA) according to the manufacturer’s
instructions. The resulting sequences were aligned with each
other and with sequences in GenBank (accession numbers:
AY297749, hMPV; M11486, hRSV-A; and D00736, hRSV-B)
with the use of BioEdit software (Ibis Therapeutics, Carlsbad,
CA, USA).
Construction of positive controls
A positive control was created by ligating the hMPV and hRSV
real-time amplification products into the pCRII-TOPO cloning
vector (TOPO TA Cloning Kit; Invitrogen, Paisley, UK)
Table 1. Nucleotide sequences of
the primers and probes used in this
study
Primer or probe Sequencea
hMPVb
Forward primer 5¢-CATATAAGCATGCTATATTAAAAGAGTCTCA-3¢ (35)
Reverse primer 5¢-CCTATTTCTGCAGCATATTTGTAATCAG-3¢ (197)
Probe 5¢-FAM-CAACHGCAGTGACACCCTCATCATTGCA-TAMRA-3¢ (95)
hRSVc
Forward primer 5¢-GCTCTTAGCAAAGTCAAGTTRAATGATACA-3¢ (15)
Reverse primer 5¢-GTTTTTGCACATCATAATTRGGAGT-3¢ (138)
Probe 5¢-VIC-CTGTCATCYAGCAAATACACTATCCAACGTAGCACAGG-TAMRA-3¢ (63)
hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.
H, mix of T, C and A; R, mix of A and G; Y, mix of C and T.
aThe location of the primers and probes is indicated in parentheses (the reference sequence for hMPV is AY145286,
and that for hRSV is X00001).
bMaertzdorf et al. [19], adapted according to the recent sequence information available in GenBank.
cDesigned as part of the present study.
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according to the manufacturer’s instructions. The identity of
the inserts was confirmed by cycle sequencing with the CEQ
DTCS Quick Start Kit on the CEQ 8000 Capillary Sequencer.
RESULTS
Optimisation of real-time PCR
The concentrations of probe and primers in the
real-time PCR for hRSV and hMPV were initially
optimised in a single real-time PCR, and were
then combined in a multiplex PCR and further
optimised using ten-fold dilution series (covering
a range of six log10 dilutions) of the hMPV and
hRSV constructs (Table 2). Sensitivities and effi-
ciencies of the two formats were comparable,
since the cut-off positive cycle threshold (Ct)
values of the multiplex assay were within
1.2 cycles of those of the single assays. Analysis
of hMPV- or hRSV-positive NPAs showed no
cross-reaction between the hMPV and the hRSV
PCR.
The specificity of the multiplex real-time PCR
was determined in two stages. First, an analysis of
all primers and probes by BLAST in GenBank
revealed no homology with sequences derived
from other organisms. Second, samples positive
for influenza virus A or B, adenovirus, parainflu-
enza viruses 1, 2 or 3, Chlamydia pneumoniae,
Mycoplasma pneumoniae, Streptococcus pneumoniae,
Haemophilus influenzae, parvovirus B19, Bordetella
or Moraxella catarrhalis were all negative when
analysed with the hMPV ⁄hRSV multiplex PCR.
Sequencing of amplicons derived from five hRSV
antigen-negative but PCR-positive samples
revealed that the amplified fragments contained
hRSV sequences.
Stability of hMPV and hRSV viral RNA in
NPAs
Knowledge concerning the stability of virus RNA
in NPAs is important in order to determine the
time-frame for analysis and the transport condi-
tions of the aspirates. Therefore, positive aspirates
(n = 5) were kept at room temperature for
1 month and RNA was extracted at different
time-points. The RNA was converted to cDNA
and analysed by multiplex real-time PCR. The
samples could be stored for up to 1 month at
room temperature without degradation of the
virus RNA (data not shown).
Comparison of hRSV antigen testing and hRSV
real-time PCR
All the NPAs collected during the two winter and
spring seasons were analysed with the hRSV
Respistrip. Of 778 NPAs analysed, 200 (25.7%)
were positive. Real-time PCR indicated the pres-
ence of the hRSV genome in all 200 of these
samples, together with an additional 106 (13.6%)
samples that were negative according to the hRSV
Respistrip.
Testing NPAs for hRSV and hMPV by real-time
PCR
Overall, 54 (6.9%) and 306 (39.3%) of 778 samples
were positive for hMPV and hRSV, respectively.
Whereas hRSV infection peaked in December,
hMPV infections were observed throughout the
entire study period (Table 3). The median age of
the hRSV-infected children was 8 months (range
1–58, mean 12 months), with the majority (66.6%;
204 ⁄ 306) of the hRSV-positive children being aged
<1 year (Table 4; Fig. 1). The hMPV-infected chil-
dren had an overall median age of 8 months
(range 1–54 months, mean 17 months) (Table 4).
Upper respiratory tract infections with hMPV
occurred predominantly during the first 2 years
of life; 72.2% (39 ⁄ 54) of the hMPV-infected
children were aged <2 years, and 53.7% (29 ⁄ 54)
were aged <1 year (Fig. 1). No significant
Table 2. Cut-off positive cycle threshold (Ct) values
obtained for the analysis of the human respiratory syncy-
tial virus (hRSV) and human metapneumovirus (hMPV)
constructs in single and multiplex real-time PCRs
Ct single PCR Ct multiplex PCR Delta Cta
Concentration hRSV
1010 copies ⁄mL 16.29 16.39 0.10
109 copies ⁄mL 20.74 21.22 0.48
108 copies ⁄mL 25.68 24.49 )1.19
107 copies ⁄mL 27.62 27.86 0.24
106 copies ⁄mL 31.25 31.61 0.36
105 copies ⁄mL 34.52 35.45 0.93
104 copies ⁄mL 39.85 40.20 0.35
R2 0.9958 0.9968
Efficiency (%) 84.20 82.60
Concentration hMPV
1010 copies ⁄mL 16.02 16.56 0.54
109 copies ⁄mL 18.98 19.82 0.84
108 copies ⁄mL 22.46 22.39 )0.07
107 copies ⁄mL 25.87 26.28 0.41
106 copies ⁄mL 29.57 30.02 0.45
105 copies ⁄mL 32.88 33.00 0.12
104 copies ⁄mL 35.83 35.90 0.07
R2 0.9992 0.9978
Efficiency (%) 98.00 101.50
aDelta Ct = Ct multiplex PCR minus Ct single PCR.
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differences in age, gender, frequencies or time of
infection were observed between the two study
periods (2003–2004 and 2004–2005). Paediatricians
affirmed that, clinically, no aetiological distinction
between hRSV- and hMPV-infected infants was
possible.
DISCUSSION
Virus infections are an important cause of ARTI in
children. The aims of the present study were to
develop and evaluate a molecular test for hRSV
and hMPV, and to determine the frequency of
these two viruses as causative agents of ARTI. A
multiplex real-time PCR using the ABI Prism 7000
system was preferred, since this approach was
already incorporated in the routine laboratory as
a diagnostic tool for other infectious agents, and
multiplexing reduces workloads.
The optimised duplex real-time PCR had a
linear range of 104)1010 copies of hMPV or
hRSV ⁄mL. The efficiency of detection was high
and was comparable with that of single-locus
PCRs. The apparent stability of the hRSV and
hMPV genomes in NPAs indicated that samples
could be stored at room temperature for at least
1 month without significant loss of detection. This
eliminates the need for special storage and trans-
port conditions, and eases the incorporation of the
test into the routine laboratory workflow.
In the present study, 778 NPAs were collected
during two winter and spring seasons. The
samples collected between November 2004 and
May 2005 were analysed prospectively on a daily
basis, and results were communicated to the
paediatricians, generally within 24 h of sample
collection. Overall, 54 (6.9%) and 306 (39.3%) of
the samples were positive for hMPV and hRSV,
respectively. These data are consistent with pre-
vious reports on hMPV-positivity obtained using
molecular detection methods for hospitalised
children with ARTI. In general, incidences of 5–
10% have been found in this specific patient
population [7,10–13,15,20–24].
Table 3. Detection of human metapneumovirus (hMPV)
and human respiratory syncytial virus (hRSV) in nasopha-
ryngeal aspirates collected between November 2003 and
May 2004 and between November 2004 and May 2005
Period










November 29 3 10 (34.5)a 2 (6.9)
December 122 47 76 (62.3) 3 (2.5)b
January 45 22 25 (55.6) 4 (8.9)
February 27 9 13 (48.1) 6 (22.2)
March 26 3 3 (11.5) 4 (15.4)
April 13 0 0 (0) 3 (23.1)
May 17 0 0 (0) 0 (0)
Subtotal 279 84 127 (45.5) 22 (7.8)
2004–2005
November 45 10 18 (40.0) 0 (0)
December 135 60 93 (68.9) 6 (4.4)
January 82 28 37 (45.1) 4 (4.9)
February 88 11 22 (25.0) 3 (3.4)
March 62 2 3 (4.8) 7 (11.3)
April 43 2 2 (4.9) 5 (11.6)
May 44 3 4 (9.1) 7 (15.9)
Subtotal 499 116 179 (35.9) 32 (6.4)
Total 778 200 306 (39.2) 54 (6.9)
Ag, antigen.
aTwo individuals had two hRSV-positive specimens obtained <5 days apart; these
were considered to be a single infection.
bOne individual had two hMPV-positive specimens obtained <4 days apart; these
were considered to be one infection.
Table 4. Comparison of the age and gender of children
infected with human metapneumovirus (hMPV) and
human respiratory syncytial virus (hRSV)
All
hMPV-positive hRSV-positive
All 2003–2004 2004–2005 All 2003–2004 2004–2005
No. samples 780 54 22 32 306 127 179
Male 399 23 9 14 147 66 81
Female 381 31 13 18 159 61 98
Age (months)
Mean 15 17 16 17 12 11 13
Median 10 8 7 9 8 7 8
Range 1–59 1–54 1–47 1–54 1–58 1–58 1–55
Fig. 1. Cumulative age distribution
of patients with human metapneu-
movirus (hMPV) or human respir-
atory syncytial virus (hRSV)
infection.
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Overall, reports of the prevalence of hMPV
differ markedly, ranging from 1.5% to 25%.
These differences might be related to the popu-
lation (age group, inpatient vs. outpatient, nega-
tivity for other viruses) and the period (winter
and spring vs. year-round) studied. Previous
reports have also suggested year-to-year varia-
tions in the frequency of hMPV [13,21,25]. Fur-
thermore, the individual real-time PCR assays
that have been described target a variety of
regions (i.e., the N, M, L, F and P genes), implying
the possibility of different performance character-
istics. The primers and probe used in the present
study targeted a part of the hMPV N-gene. Cote
et al. [26] reported that PCR assays that amplify
the N gene have superior specificities and sensi-
tivities, and the primers and probe were adapted
to cover all hMPV variants found in GenBank.
hMPV and hRSV circulated in the present
study population throughout the study periods
(except for May 2004), confirming the seasonal
circulation described previously [5,7,18,27,28]. In
both years, hMPV infections could be found
during the entire study period, with a slight
increase in frequency from February onwards, but
no significant peak in hMPV infection was detec-
ted. In contrast, the frequency of hRSV infection
was higher in the winter months, with significant
peaks during December 2004 and December 2005
(Table 3). Boivin et al. [20] and McAdam et al. [29]
reported hMPV outbreaks in shorter periods
compared with hRSV. The present study did not
support this observation, as the outbreaks of
hRSV and hMPV were distributed equally during
both periods (Table 3). Several previous studies
have documented hMPV infection during the
winter and spring periods [10,28–31], but most
studies published previously cover only one
season, which does not allow a good definition
of the seasonality of hMPV. In the present study,
hRSV activity peaked in both periods during
December, suggesting that this seasonal distribu-
tion is an annual occurrence [7,29].
The present study analysed NPAs obtained
from children aged <60 months. This selection
was based on seroprevalence surveys indicating
that virtually all children are infected by the age
of 5–10 years [5,9,32]. ARTI with hMPV was
found to occur predominantly during the first
2 years of life, with 72.2% of the hMPV-infected
children being aged <2 years, and 53.7% being
aged <1 year. Several reports have suggested that
hospitalised children experience an hMPV infec-
tion at an older age compared to hRSV [20,22,24],
and this tendency was also observed in the
present study, with 66.6% (204 ⁄ 306) of the detec-
ted hRSV infections occurring in children aged
<1 year, compared with only 53.7% (29 ⁄ 54) of the
hMPV infections. A greater proportion of hRSV
infections (23.6% vs. 14.8% hMPV infections) also
occurred in very young infants (aged <3 months).
The mean age for hRSV infection was 12 months,
compared with 17 months for hMPV.
All samples (n = 778) were tested for both
hMPV and hRSV in order to detect co-infections
with these viruses. Greensill et al. [18] reported a
high frequency of hMPV-positive children with
severe hRSV infection, raising the possibility that
hMPV might influence the severity of hRSV
disease. A report from Germany, focusing on
children in the intensive care unit, reported a total
hMPV prevalence of 18% (n = 15); of these
children, 60% were also hRSV-positive [33].
However, in the present study, only three of the
54 hMPV-positive samples were also positive for
hRSV by real-time PCR, and one of these samples
was positive for hMPV, hRSV and influenza A
virus. In another patient, hMPV and hRSV were
found 2 weeks apart (data not shown). The
present study also found that the male:female
ratio for hMPV-positive patients was 1:1.4 in
2003–2004 and 1:1.3 in 2004–2005. These data are
in contrast to results from other studies, and to
the fact that males are associated with an
increased risk of respiratory tract disease caused
by respiratory viruses [15,34].
Using the routine hRSV antigen test, a patho-
gen was identified in only 26% (200 ⁄ 778) of the
individuals tested. The real-time multiplex PCR
revealed a causative viral agent in an additional
160 (20.6%) specimens. hMPV was present in
9.3% (54 ⁄ 578) of all cases of ARTI with no other
virological diagnosis. It was concluded that hRSV
and hMPV are both significant causes of ARTI in
children aged <5 years. These viruses co-circulate
at high frequencies in winter and spring, and
rapid and sensitive detection is required in order
to give optimal care to patients. The fact that the
real-time PCR assay is relatively rapid and is
more sensitive than the hRSV antigen test makes
it a valuable tool for the clinician. Further studies
are needed to reveal the impact of rapid diagnosis
of viral infections on clinical decision-making and
antibiotic prescription patterns.
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